Published On: Thu, Sep 22nd, 2016

FY2019 Earnings Estimate for Pfizer Inc. (PFE) Issued By Leerink Swann

Pfizer Inc. (NYSE:PFE) – Stock analysts at Leerink Swann lowered their FY2019 EPS estimates for shares of Pfizer in a report issued on Tuesday. Leerink Swann analyst S. Fernandez now anticipates that the firm will post earnings per share of $2.78 for the year, down from their previous estimate of $2.85. Leerink Swann also issued estimates for Pfizer’s FY2020 earnings at $2.68 EPS.
Several other equities analysts have also recently issued reports on the company. Jefferies Group lowered their price objective on Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a research report on Tuesday, September 13th. Argus reiterated a “buy” rating and set a $39.00 target price on shares of Pfizer in a research note on Sunday, August 28th. Bank of America Corp. set a $40.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, August 23rd. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $40.00 target price on shares of Pfizer in a research note on Tuesday, August 23rd. Ten analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $38.78.
Pfizer (NYSE:PFE) traded down 0.29% during trading on Thursday, hitting $34.18. The stock had a trading volume of 13,086,301 shares. The company has a market cap of $207.32 billion, a price-to-earnings ratio of 30.30 and a beta of 0.87. The company has a 50-day moving average price of $34.74 and a 200-day moving average price of $33.87. Pfizer has a 52-week low of $28.25 and a 52-week high of $37.39.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/fy2019-earnings-estimate-for-pfizer-inc-pfe-issued-by-leerink-swann.html

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The firm earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same period last year, the company earned $0.56 earnings per share. The business’s revenue for the quarter was up 10.9% on a year-over-year basis.
A number of hedge funds have recently made changes to their positions in PFE. Nelson Roberts Investment Advisors LLC raised its position in shares of Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 189 shares during the period. Stelac Advisory Services LLC bought a new position in shares of Pfizer during the second quarter worth approximately $110,000. Tuttle Tactical Management LLC bought a new position in shares of Pfizer during the second quarter worth approximately $117,000. Catamount Wealth Management raised its position in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares during the period. Finally, Delphi Private Advisors LLC raised its position in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 47 shares during the period. 69.65% of the stock is owned by institutional investors and hedge funds.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Receive News & Ratings for Pfizer Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>